Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.47 |
| ▸ | FAP | Q12884 | 3/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102749 | 1.00 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL111112 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL296935 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL1951493 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL25318201 | 0.93 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL9512271 | 0.93 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL9512282 | 0.93 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2735523 | 0.93 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL15203539 | 0.93 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19982029 | 0.93 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | DPP4 4071/4885DPP7 2847/4885DPP8 3018/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | DPP4 4071/4885DPP7 2847/4885DPP8 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.